Experts Urge Nuanced Choice Between Vismodegib and Sonidegib in Advanced BCC

Vismodegib and sonidegib should not be treated as interchangeable options in advanced basal cell carcinoma, because the two oral hedgehog pathway inhibitors differ in pharmacokinetics, dosing logistics, monitoring requirements and the timing of adverse effects. That was the central message from a November 5, 2026, Dermatology Times Case-Based Roundtable in San Diego, California, led by Vishal A. Patel, MD, FASDS, FACMS, associate professor of dermatology and hematology/oncology at The George Washington University School of Medicine and Health Sciences and director of the Cutaneous Oncology Program at The George Washington University Cancer Center.

The session, titled "Differentiating Hedgehog Pathway Inhibitors in Advanced Basal Cell Carcinoma," used interactive polling and clinical case scenarios to examine how dermatologists choose between the two agents, manage toxicity and identify patients who may benefit from systemic treatment.

How should clinicians define 'difficult to treat' BCC?

Patel pushed participants to define locally advanced and difficult-to-treat BCC more broadly than technical resectability. Tumor location, size, depth of invasion and the potential need for complex reconstruction all shape the treatment decision, and panelists conceded that a tumor a surgeon can remove is not always a tumor a patient should have removed.

One case involved an infiltrative BCC of the medial canthus extending toward the nasal sidewall. Participants weighed the challenges of surgical reconstruction against the possibility of systemic therapy before an invasive intervention, and stressed multidisciplinary collaboration and shared decision-making for tumors in anatomically sensitive sites.

What separates vismodegib from sonidegib in practice?

Both agents inhibit the hedgehog signaling pathway, yet participants highlighted differences in pharmacokinetic properties, dosing requirements, adverse-effect profiles and monitoring considerations. Patel emphasized understanding those distinctions rather than treating the drugs as substitutes.

Prescribing familiarity remains a significant driver of selection. Several participants reported more experience with vismodegib from training or prior clinical use; others described limited experience with either drug. Insurance coverage, concomitant medications, institutional experience and patient-specific factors also influence the choice. The group discussed how half-life differences may influence the timing of adverse effects, treatment interruptions and patient counseling.

How should muscle spasms and monitoring burdens be handled?

Tolerability emerged as a major concern. One participant described prescribing vismodegib in a prior experience where severe muscle spasms and the demands of adverse-effect management created reluctance to use HHIs again.

Patel presented a case of a patient on vismodegib who developed grade 2 muscle spasms interfering with daily activities, with a creatine kinase level roughly twice the upper limit of normal, prompting discussion of treatment modification. Participants considered temporary interruptions, supportive management and laboratory monitoring. They also debated whether differences in drug half-life affect symptom resolution after discontinuation. Panelists insisted adverse-effect counseling should start before treatment initiation, so patients know what symptoms to report.

What happens when patients decline surgery?

Another scenario involved a 52-year-old man with an ulcerated, infiltrative BCC on the nasal tip, with concern for deep invasion and possible cartilage involvement. Working in custom cabinetry, he declined surgery and radiation because of feared disruption to his daily life.

The panel agreed that decisions must account for more than tumor characteristics — occupational responsibilities, cosmetic concerns and patient preferences all matter. They discussed HHIs as a component of treatment planning for selected patients, potential tumor reduction before subsequent treatment, and the challenge of determining appropriate treatment duration.

Should treatment goals differ by patient?

Goals should vary with age, overall health, life expectancy and disease burden, participants said. Younger patients may prioritize durable tumor clearance; older patients or those with significant comorbidities may value symptom relief, preservation of function and a lower treatment burden. Outcomes beyond tumor shrinkage — duration of response, disease control and tolerability — deserve evaluation, and goals should be reassessed when adverse effects or shifting preferences affect feasibility.

What did participants take away?

Several attendees said the side-by-side review of vismodegib and sonidegib increased their confidence in discussing systemic options. Some admitted HHIs were not routinely raised during initial surgical consultations, and others expressed interest in learning more about selection and toxicity management. Patel closed by reinforcing that individualized decisions should incorporate patient history, comorbidities, concomitant medications and therapeutic goals — a move beyond a surgery-first framework for every patient with difficult-to-treat BCC. The session suggests that as HHI familiarity grows, dermatologists may become better equipped to deploy nonsurgical strategies and optimize long-term disease management.

The roundtable referenced the NCCN Clinical Practice Guidelines in Oncology for Basal Cell Skin Cancer, Version 1.2026, and the 12-month analysis of the phase 2 BOLT trial of sonidegib published in the Journal of the American Academy of Dermatology in 2016.